Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Published byFelicity Crawford Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:"— Presentation transcript:

1 Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study  François Spertini, MD, Gilles DellaCorte, MD, Alexander Kettner, PhD, Frédéric de Blay, MD, PhD, Lars Jacobsen, PhD, Marek Jutel, MD, Margitta Worm, MD, Vincent Charlon, PhD, Christophe Reymond, PhD  Journal of Allergy and Clinical Immunology  Volume 138, Issue 1, Pages (July 2016) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Trial profile. Flow diagram illustrating the numbers of subjects screened, randomized, treated, and evaluated during the study. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 RSMSs and pollen exposure during the birch pollen season. The start of the birch pollen season (D0) was set as the first of 3 consecutive days with at least 10 pollen grains/m3. Regional birch pollen air concentration was measured separately in Denmark and Sweden, Latvia/Lithuania, Poland, and France/Switzerland (gray shaded areas). Daily RSMSs (right axis) are reported as smoothed curves in green for placebo, red for 50 μg of Bet v 1 COPs, and blue for 100 μg of Bet v 1 COPs. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Differences from placebo for the Bet v 1 COP–treated groups: A, RSMS; B, MiniRQLQ score; and C, NNSS. LS mean differences of the indicated scores are plotted relative to placebo (green line) for 50 μg of Bet v 1 COPs (red) and 100 μg of Bet v 1 COPs (blue). Ninety-five percent confidence limits are indicated as horizontal colored lines. Analyses were performed during the 2013 birch pollen season on the mITT set. P values were determined by using ANCOVA, with treatment and geographic region as independent factors in the model. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Effect of treatment on levels of Bet v 1–specific IgG4 and IgE. A, Bet v 1–specific IgG4 levels were measured by using ELISA in sera from Bet v 1 COP– and placebo-treated patients of the mITT set before treatment (V0 and V1), 30 days after treatment (V11), at the peak season (V13), and about 14 days after the season (V14). B, Fold increase over baseline in Bet v 1–specific IgG4 levels was calculated for each patient at the indicated visits. Medians (solid line) are displayed within solid boxes showing 25th to 75th percentiles. Whiskers expand to the 10th and 90th percentile, and individual outliers are shown as colored dots. C, Fold increase over baseline in Bet v 1–specific IgE levels was calculated for each patient at the indicated visits and is displayed as indicated in Fig 4, A and B. NS, Not significant (P > .05). *.05 > P > .001, **.001 > P > .0001, and ***.0001 > P, as determined by using the Wilcoxon signed rank test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Safety analysis, local and systemic AEs, and FEV1 decreases. A, Frequency of treatment-emergent local AEs at the administration site stratified by clinical description and recorded on the safety set (any patient receiving ≥1 injection). B, All systemic AEs with a frequency of 5% or greater stratified by clinical description and recorded on the safety set. C, Frequency of self-tested FEV1 decreases (ΔFEV1) of more than 30% stratified by injections 1 to 5. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:"

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,

Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,
Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Similar presentations

Ads by Google